The FDA has approved guselkumab(Tremfya) for both subcutaneous (SC) and intravenous (IV) induction therapy treatment of adults with moderately to severely active Crohn’s disease (CD). It is the only IL-23 inhbitor available for SC and IV use in CD https://t.co/ekXRVOwNnS https://t.co/6zveRR5WjD
Links:
U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor off…
https://buff.ly/MwWnOfQ
Mar-20-2025
